FK506 Augments Activation-induced Programmed Cell Death of T Lymphocytes In Vivo

Kiyoshi Migita, Katsumi Eguchi, Yojiro Kawabe, Toshiaki Tsukada, Akinari Mizokami, and Shigenobu Nagataki
The First Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki 852, Japan

Abstract

FK506 is an immunosuppressive drug that inhibits T cell receptor–mediated signal transduction. This drug can induce immunological tolerance in allograft recipients. In this study, we investigated the in vivo effects of FK506 on T cell receptor–mediated apoptosis induction. Injection of anti-CD3 antibody (Ab) in mice resulted in the elimination of CD4+ CD8+ thymocytes by DNA fragmentation. FK506 treatment significantly augmented thymic apoptosis induced by in vivo anti-CD3 Ab administration. Increased thymic apoptosis resulted in the disappearance of CD4+ CD8+ thymocytes after anti–CD3 Ab/FK506 treatment. DNA fragmentation triggered by FK506 was induced exclusively in antigen-stimulated T cells, since enhanced DNA fragmentation induced by in vivo staphylococcal enterotoxin B (SEB) injection was confirmed in SEB-reactive Vβ8+ thymocytes but not in SEB-nonreactive Vβ6+ thymocytes. In addition to thymocytes, mature peripheral T cells also die by activation-induced programmed cell death. A similar effect of FK506 on activation-induced programmed cell death was observed in SEB-activated peripheral spleen T cells. In contrast, cyclosporin A treatment did not enhance activation-induced programmed cell death of thymocytes and peripheral T cells. Apoptosis is required for the generation and maintenance of self-tolerance in the immune system. Our findings suggest that FK506-triggered apoptosis after elimination of antigen-activated T cells may represent a potential mechanism of the immunological tolerance achieved by FK506 treatment. (J. Clin. Invest. 1995. 96:727–732.) Key words: FK506 • apoptosis • superantigen • immunological tolerance • T cells

Introduction

FK506, a macrolide lactone isolated from Streptomyces tsukubaensis, is a potent immunosuppressive agent (1, 2). It is used clinically in organ transplantation, such as liver, kidney, and pancreas (3, 4). It is well accepted that FK506 acts by strongly inhibiting lymphokine production by T cells (5–7). However, little is known about the in vivo immunosuppressive effects of FK506. Furthermore, in vivo FK506 studies have assessed its pharmacological effects on allograft survival but have not addressed its in vivo effect on T cell activation and immunosuppression. This study was prompted by several previous studies reporting the induction of immunological tolerance by FK506. We hypothesized that FK506 can establish immunological tolerance in vivo by affecting T cell apoptosis.

The establishment of T cell tolerance is known to occur primarily in the thymus gland, where autoreactive T cells are deleted by apoptosis (8, 9). However, similar to thymocytes, peripheral T cells surviving thymic selection may undergo apoptosis by antigen-mediated stimulation (10, 11). Apoptosis, also termed programmed cell death, is a signal-dependent suicide form of cell death and is required for the generation and maintenance of self-tolerance (12, 13). Several stimuli induce apoptosis, including stimulation of T and B cells via antigen receptors, irradiation, and exposures to cytokines, such as TNF and TGF-β (14–17).

In the present series of experiments, we examined the in vivo effect of FK506 on the T cell activation-induced programmed cell death triggered by T cell receptor–mediated stimulation. Our results showed that in vivo FK506 treatment eliminated antigen-stimulated T cells through DNA fragmentation. Alloantigen-stimulated cytolytic T cells contribute to the rejection of transplanted allografts and graft-versus-host disease (GVHD). The elimination of these activated cytolytic T cells may silence these phenomena. Our results suggest that FK506-induced apoptosis of antigen-stimulated T cells may represent one of the mechanisms of immunological tolerance.

Methods

Antibodies and reagents

Murine anti-CD3 specific monoclonal antibody (mAb) producing B cell hybridoma 2C11 (18) was kindly provided by Dr. J. A. Bluestone (University of Chicago, Chicago, IL). Monoclonal anti-CD3 Ab was purified in our laboratory using Protein G–Sepharose column (Pharmacia Biotech, Uppsala, Sweden) from culture supernatant. Anti-Vβ8.1, 2, 3 specific monoclonal antibody producing B cell hybridoma F23.1 (19) was kindly provided by Dr. M. J. Bevan (Research Institute of Scripps Clinic, La Jolla, CA). The antibody was purified and biotinylated in our laboratory. Phycoerythrin (PE)–anti-CD4 and FITC–anti-CD8 Ab were purchased from Becton Dickinson (Mountain View, CA). FK506 and cyclosporin A (CsA) were kindly provided by Fujisawa Pharmaceuticals (Osaka, Japan) and Sandoz (Tokyo, Japan). All other reagents were purchased from Sigma Immunochemicals (St. Louis, MO).

1. Abbreviations used in this paper: CsA, cyclosporin A; GVHD, graft-versus-host disease; PE, phycoerythrin; SEB, staphylococcal enterotoxin B.
**Mice**

Bab/c mice (3–4 wk old) were obtained from Japan SLC, Inc. (Hama-
matsu, Japan). Mice were injected intraperitoneally with anti-CD3 Ab (30 μg), staphylococcal enterotoxin B (SEB, 50 μg; Sigma Immuno-
chemicals), FK506 (2 mg/kg), or CsA (50 mg/kg).

**Cell preparation**

Spleen T cells. Spleen single cell suspensions were isolated and treated with Tris-buffered 0.16 M ammonium chloride to lyse red blood cells. T cells were enriched by depletion of surface IgG-positive cells on goat anti–mouse IgG (100 μg/ml)–coated Petri dishes. Nonadherent cells were further incubated with anti–rat IgG–coated Fe3O4 cross-reactive to mouse IgG (Dynabeads M450; DYNAL, Oslo, Norway), and then sorted by magnetically activated cell sorter (MACS; Miltenyi Biotec GmbH, Meilzfeld, Germany). This process resulted in a negatively selected CD3-positive T cell population (~ 95% of CD3+ cells). This population will be referred to as spleen T cells.

**DNA fragmentation assay**

Thymocytes were washed with cold phosphate-buffered saline solution (PBS). Fresh or cultured thymocytes were collected by centrifugation at 200 g for 10 min. The pellets were lysed with 1.0 ml of lysis buffer (10 mM Tris, pH 7.5, 1.0 mM EDTA, 0.2% Triton X-100). The lysis was centrifuged at 13,000 g for 10 min, and the supernatant containing fragmented DNA was collected. DNA was precipitated overnight at −20°C in 50% isopropanol and 0.5 M NaCl. The precipitate was collected after centrifugation at 13,000 g, air-dried, and suspended in 10 mM Tris, 1.0 mM EDTA, pH 7.5. A loading buffer containing 15 mM EDTA, 2% SDS, 50% glycerol, and 0.05% bromophenol blue was added at 1:5 (vol/vol). Samples were heated at 65°C for 10 min and electrophoresed in a 1% agarose gel. Electrophoresis was carried out in 10 mM Tris-phosphate, 2 mM EDTA, pH 8.0. Gels were later stained with 0.5 μg/ml ethidium bromide, and visualization of DNA was accomplished using ultraviolet light.

**FACS® analysis**

Thymocytes from each thymus gland were counted and stained with FITC–anti-CD8 and PE–anti-CD4 monoclonal antibodies for 30 min on ice. Spleen single cell suspensions were treated with Tris-buffered 0.16 M ammonium chloride to lyse red blood cells. Spleen cells were treated with biotin-conjugated anti-V88 or anti-V86 monoclonal antibody for 30 min on ice. The washed cells were incubated with FITC-avidin and PE–anti-CD4 antibody. Stained cells were analyzed using EPICS PROFILE (Coulter Corp., Hialeah, FL) flow cytometer. In a few experiments, apoptosis was quantified by flowcytometric determination of the proportion of cells with hypodiploid DNA using the method of Perandone et al. (20). Spleen T cells were resuspended in 1.0 ml of hypotonic PI solution (3.4 mM sodium citrate, 50 μg/ml propidium iodide, 0.1% Triton X-100, 1.0 mM Tris, 0.1 mM EDTA) and stored in darkness on ice until they were analyzed by FACS®. Apoptotic nuclei were distinguished by their hypodiploid DNA content compared with the diploid DNA content of normal nuclei.

**Results**

FK506 augmented anti-CD3 Ab–induced thymic apoptosis. It is known that in vivo administration of anti-CD3 Ab causes the deletion of immature thymocytes by apoptosis (21). Using this system, we examined the in vivo effect of FK506 and CsA on thymocyte activation-induced programmed cell death. To detect DNA fragmentation, freshly prepared mice thymocytes were analyzed by agarose gel electrophoresis 16 h after anti-CD3 Ab, CsA, or FK506 injection. As shown in Fig. 1, DNA fragmenta-
tion was not observed in thymocytes of PBS, CsA (50 mg/kg), or FK506 (2 mg/kg) injected mice. Fragmentation of thymocyte DNA occurred 16 h after anti-CD3 Ab (30 μg) injection. A simultaneous injection of anti-CD3 Ab and FK506 was followed 16 h later by examination of thymocyte DNA fragmentation. FK506 significantly enhanced thymic DNA fragmenta-
tion induced by anti-CD3 Ab stimulation. In contrast, in vivo CsA treatment partially inhibited anti-CD3 Ab–induced thymic apoptosis (Fig. 1).

We also analyzed the surface expression of CD4 and CD8 molecules on thymocytes after anti-CD3 Ab, CsA, or FK506 injection (Fig. 2). In vivo anti-CD3 Ab administration reduced CD4+ CD8+ thymocytes. Treatment with anti-CD3 Ab and FK506 caused a more marked deletion of CD4+ CD8- immature thymocytes compared with that observed with anti-CD3 Ab alone. But in vivo CsA treatment did not enhance the deletion of CD4+ CD8- thymocytes induced by anti-CD3 Ab.

FK506 augmented SEB-induced thymic apoptosis in vivo. Administration of SEB, a bacterial superantigen, is known to induce the antigen-specific thymocyte elimination by apoptosis (22). We investigated the effect of FK506 on SEB-induced thymic apoptosis. Analysis of DNA extracted from SEB (50 μg)-injected mice thymocytes was performed using agarose gel electrophoresis. As shown in Fig. 3A, some DNA fragmentation was observed in SEB-primed thymocytes 16 h after injection. However, DNA fragmentation was better enhanced in SEB-FK506–primed mice thymocytes. To determine whether the latter occurred selectively in SEB-activated thymocytes, we analyzed the DNA of SEB-reactive V88-positive thymocytes.
Figure 2. FK506 enhanced anti-CD3 Ab–induced deletion of CD4+CD8+ thymocytes in vivo. Balb/c mice were intraperitoneally injected with PBS, CsA, FK506, anti-CD3 Ab, or anti-CD3 Ab and CsA, or anti-CD3 Ab and FK506. After 24 h, thymus glands were removed, and thymocytes were stained with FITC–anti-CD8 and PE–anti-CD4 mAb and analyzed by flow cytometer. Cell numbers per thymus of triplicate treated mice were also determined. PBS, 108.3±11.8; CsA, 102.4±13.4; FK506, 98.7±21.0; anti-CD3 Ab, 40.5±4.2; anti-CD3 Ab+CsA, 44.5±5.5; anti-CD3 Ab+FK506, 35.5±3.8. (cells/gland, in millions).

FK506 augmented peripheral T cell apoptosis induced by in vivo SEB administration. SEB (50 µg) was injected intravenously into mice that were killed 3 d later. As previously reported, after 2 h of in vitro culture, the DNA of SEB-primed spleen T cells had a ladder-like pattern, characteristic of apoptosis (10). On day 3 after SEB administration, FK506 (2 mg/kg), CsA (50 mg/kg), or PBS was injected into mice that were killed 6 h later. The spleen T cells were cultured for 2 h in vitro, and fragmented DNA was extracted and electrophoresed. Increased DNA fragmentation was detected in FK506-treated spleen T cells compared with PBS-treated spleen T cells. But the DNA fragmentation of CsA-treated spleen T cells was not changed compared with that of PBS-treated spleen T cells (Fig. 4A). Furthermore, DNA fragmentation was observed in freshly isolated SEB-primed spleen T cells treated with FK506 for 6 h in vivo (Fig. 4B). We measured the percentage of Vβ8+ T cells, the population supposed to have undergone apoptosis, between FK506- or PBS-treated mice before the start of the in vitro culture. However, there was no difference in the percentage of SEB-primed Vβ8+ T cells on day 3 between both mice (data not shown).

We also measured the percentage of the apoptotic T cells with hypodiploid DNA content by FACS® analysis. Flow cytometric analysis showed an increase in SEB-primed T cells with hypodiploid DNA in FK506-treated mice compared with control mice (data not shown).

Profound reduction of Vβ8+CD4+ T cells in SEB-FK506–treated mice. In vivo administration of SEB induced a partial elimination of SEB-reactive Vβ8+ T cells. 3 d after injection of SEB, mice were injected with FK506, CsA, or PBS, and analysis of the percentage of Vβ8+CD4+ or Vβ6+CD4+ in spleen T cells was performed on day 7. As expected, enhanced deletion of Vβ8+CD4+ was observed in FK506-treated murine...
spleen T cells (Fig. 5 A). However, the percentage of control Vβ6+ CD4+ T cells in FK506-treated was not different from that of untreated mice (Fig. 5 B). We measured the percentage of CD4+ Vβ8+ T cells in several PBS- or SEB-treated mice and confirmed that this enhancement on CD4+ Vβ8+ T cell deletion was consistently induced by in vivo FK506 treatment (Table 1). In vivo injection of SEB also induces a state of anergy in peripheral T cells, when T cells are challenged with SEB in vitro (23). However, in vivo FK506 treatment failed to influence SEB-induced anergy state (data not shown).

**Discussion**

FK506 is a powerful immunosuppressant drug used clinically to prevent allograft rejection (1–4). In vitro studies have dem-

### Table 1. FK506 Enhances Elimination of CD4+ Vβ8+ T Cells in SEB-treated Mice

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Percentage of positive cellsa</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CD4+ Vβ8+</td>
</tr>
<tr>
<td>PBS</td>
<td>25.7±2.1</td>
</tr>
<tr>
<td>PBS/FK506</td>
<td>26.2±1.8</td>
</tr>
<tr>
<td>SEB</td>
<td>20.6±2.7</td>
</tr>
<tr>
<td>SEB/FK506</td>
<td>14.5±1.9</td>
</tr>
</tbody>
</table>

*Spleen cell suspensions were prepared from four groups of treated mice 7 d after PBS or SEB injection and analyzed for expression for CD4 and Vβ by flowcytometer. FK506 was injected 3 d after PBS or SEB injection. Data represent the average of triplicate samples. †There was little difference of total T cell numbers in these four groups of treated mice.*

FK506 enhanced the reduction of CD4+ Vβ8+ T cells induced by in vivo SEB administration. Balb/c mice were injected intraperitoneally with PBS or SEB (50 μg). After 72 h of injection, mice were injected with CsA (50 mg/kg), FK506 (2 mg/kg), or PBS. On day 7 after the first injection, mice were killed, and spleen T cells were stained with anti-Vβ8 (FITC, A) or anti-Vβ6 (B) and anti-CD4 (PE) and analyzed by a flowcytometer.

---

730 Migita et al.
onstrated that FK506 and CsA block T cell activation by inhibiting T cell receptor–mediated transcription of IL-2 gene (5–7). After organ transplantation, the promotion of T cell tolerance to alloantigen may be established by FK506, but the precise effect of FK506 on in vivo alloantigen-activated T cells is not well understood. It is possible that under the continuous presence of alloantigen chronically stimulated T cells may be negatively regulated by FK506. Alternatively, allotolerance may be induced by the deletion of alloantigen-stimulated immunocomponents.

In our experiments, we investigated the effects of FK506 on apoptosis of antigen-stimulated thymocytes and peripheral T cells. Our results demonstrated that DNA fragmentation of thymocytes, induced by anti-CD3 Ab stimulation, was augmented by in vivo FK506 treatment. Such a phenomenon was associated with a profound disappearance of CD4+ CD8+ thymocytes. To determine whether FK506 enhances apoptosis exclusively in antigen-stimulated T cells, we used a superantigen to induce thymic apoptosis. Taking advantage of the property of Vβ8 specificity of SEB (24), we also examined the effect of FK506 on SEB-mediated thymic apoptosis. Our results confirmed that FK506 augments DNA fragmentation of antigen-stimulated thymocytes exclusively, as made evident by the detection of a significant DNA ladder pattern observed in SEB-reactive Vβ8-positive thymocytes but not in SEB-nonreactive Vβ6-positive thymocytes.

As well as thymocytes, mature T cells are subject to clonal elimination as demonstrated in studies using different superantigens, such as the mouse mammary tumor virus–encoded antigen or bacterial superantigens (10, 11). We examined the effect of FK506 on in vivo SEB-activated spleen T cells. Our results demonstrated that in vivo FK506 treatment enhanced DNA fragmentation of SEB-activated spleen T cells. The augmented DNA fragmentation resulted in a profound reduction of CD4+ Vβ8+ population in SEB-FK506–treated mice.

Our results demonstrated that CsA partially blocked anti-CD3–induced in vivo thymic apoptosis in agreement with a previous report (25). Although both drugs have indistinguishable effect by blocking the transcription of IL-2 gene, CsA and FK506 may have a differential effect on thymic apoptosis in vivo. For example, CsA is responsible for the induction of T cell–mediated autoimmune under certain circumstances (26, 27). In contrast to the inhibitory effect on thymic apoptosis in vivo, repeated CsA injection increases the deletion of peripheral T cells stimulated by SEB (28).

FK506 treatment improves immunosuppressive therapy for allograft rejection (29, 30). Tolerance to allograft, induced by FK506, may be attributed to the molecular action of FK506 by inhibiting the signal transduction of alloactivated T cells. Our results suggest an additional possible mechanism for the immunological tolerance established by FK506. FK506 may induce tolerance to allograft by provoking the elimination of alloantigen-activated T cells by apoptosis. In this regard, Bishop et al. (31) recently demonstrated that FK506 prevented the generation of alloantigen-induced cytolytic and helper T lymphocytes by limiting the dilution assay. GVHD is also a systemic manifestation of transplanted T lymphocyte activation in response to alloantigen (32). Furthermore, recent studies have demonstrated that FK506 treatment prolongs GVHD-free stage by removing alloantigen-stimulated donor T lymphocytes and that FK506 is superior to CsA in preventing GVHD stage (33, 34).

These reports support our hypothesis that alloantigen-stimulated T cells may be deleted by in vivo FK506 treatment.

In summary, our results indicate that in vivo FK506 treatment eliminates antigen-stimulated T cells by apoptosis. This FK506-mediated elimination of activated T cells may represents a new mechanism of FK506-induced immunological tolerance to alloantigen.

Acknowledgment

This work was supported by Fujisawa Pharmaceuticals.

References


Effects of FK506 on T Cell Apoptosis


